Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Safety, Efficacy, & PK of Pegunigalsidase Alfa (PRX-102) 2 mg/kg IV Administered Every 4 Weeks in Fabry Disease Patients (BRIGHT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03180840
Recruitment Status : Active, not recruiting
First Posted : June 8, 2017
Last Update Posted : September 26, 2019
Sponsor:
Information provided by (Responsible Party):
Protalix

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : December 2020